Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study

Our primary aim was to compare the therapeutic index (tumor–to–bone marrow and tumor-to-kidney absorbed-dose ratios) of the new radiolabeled somatostatin receptor antagonist [¹⁷⁷Lu]Lu-DOTA-JR11 with the established radiolabeled somatostatin receptor agonist [¹⁷⁷Lu]Lu-DOTATOC in the same patients with progressive, standard therapy-refractory meningioma. Methods: In this prospective, single-center, open-label phase 0 study (NCT04997317), 6 consecutive patients were included: 3 men and 3 women (mean age, 63.5 y). Patients received 6.9–7.3 GBq (standard injected radioactivity) of [¹⁷⁷Lu]Lu-DOTATOC followed by 3.3–4.9 GBq (2 GBq/m² × body surface area) of [¹⁷⁷Lu]Lu-DOTA-JR11 at an interval of 10 ± 1 wk. In total, 1 [¹⁷⁷Lu]Lu-DOTATOC and 2–3 [¹⁷⁷Lu]Lu-DOTA-JR11 treatment cycles were performed. Quantitative SPECT/CT was done at approximately 24, 48, and 168 h after injection of both radiopharmaceuticals to calculate meningioma and organ absorbed doses as well as tumor-to-organ absorbed-dose ratios (3-dimensional segmentation approach for meningioma, kidneys, liver, bone marrow, and spleen). Results: The median of the meningioma absorbed dose of 1 treatment cycle was 3.4 Gy (range, 0.8–10.2 Gy) for [¹⁷⁷Lu]Lu-DOTATOC and 11.5 Gy (range, 4.7–22.7 Gy) for [¹⁷⁷Lu]Lu-DOTA-JR11. The median bone marrow and kidney absorbed doses after 1 treatment cycle were 0.11 Gy (range, 0.05–0.17 Gy) and 2.7 Gy (range, 1.3–5.3 Gy) for [¹⁷⁷Lu]Lu-DOTATOC and 0.29 Gy (range, 0.16–0.39 Gy) and 3.3 Gy (range, 1.6–5.9 Gy) for [¹⁷⁷Lu]Lu-DOTA-JR11, resulting in a 1.4 (range, 0.9–1.9) times higher median tumor–to–bone marrow absorbed-dose ratio and a 2.9 (range, 2.0–4.8) times higher median tumor-to-kidney absorbed-dose ratio with [¹⁷⁷Lu]Lu-DOTA-JR11. According to the Common Terminology Criteria for Adverse Events version 5.0, 2 patients developed reversible grade 2 lymphopenia after 1 cycle of [¹⁷⁷Lu]Lu-DOTATOC. Afterward, 2 patients developed reversible grade 3 lymphopenia and 1 patient developed reversible grade 3 lymphopenia and neutropenia after 2–3 cycles of [¹⁷⁷Lu]Lu-DOTA-JR11. No grade 4 or 5 adverse events were observed at 15 mo or more after the start of therapy. The disease control rate was 83% (95% CI, 53%–100%) at 12 mo or more after inclusion. Conclusion: Treatment with 1 cycle of [¹⁷⁷Lu]Lu-DOTA-JR11 showed 2.2–5.7 times higher meningioma absorbed doses and a favorable therapeutic index compared with [¹⁷⁷Lu]Lu-DOTATOC after injection of 1.4–2.1 times lower activities. The first efficacy results demonstrated a high disease control rate with an acceptable safety profile in the standard therapy for refractory meningioma patients. Therefore, larger studies with [¹⁷⁷Lu]Lu-DOTA-JR11 are warranted in meningioma patients.